| |
| |
|
| Insider
Information: |
Lubner David Charles |
| Relationship: |
Director |
| City: |
Watertown |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
144,554 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,373,596 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
144,554 |
|
|
| Total
Value |
$1,373,596 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Tetraphase Pharmaceuticals Inc |
TTPH |
SVP and CFO |
2015-08-14 |
69,270 |
|
0 |
Premium* |
|
|
Ra Pharmaceuticals, Inc. |
RARX |
Executive VP and CFO |
2020-04-02 |
0 |
2019-02-01 |
0 |
Premium* |
|
|
Nightstar Therapeutics Plc |
NITE |
Director |
2019-06-07 |
0 |
2019-06-07 |
0 |
Premium* |
|
|
Dyne Therapeutics, Inc. |
DYN |
Director |
2020-09-21 |
53,625 |
2020-09-21 |
0 |
Premium* |
|
|
Arcellx, Inc. |
ACLX |
Director |
2022-02-08 |
21,659 |
2022-02-08 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
22 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ACLX |
Arcellx, Inc. |
Director |
– • – |
2022-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
21,659 |
21,659 |
0 |
- |
|
| DYN |
Dyne Therapeutics, Inc. |
Director |
– • – |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
53,625 |
53,625 |
0 |
- |
|
| RARX |
Ra Pharmaceuticals, Inc. |
Executive VP and CFO |
• – – |
2020-04-02 |
4 |
D |
$48.00 |
$749,856 |
D/D |
(15,622) |
0 |
0 |
- |
|
| NITE |
Nightstar Therapeutics Pl... |
Director |
– • – |
2019-06-07 |
4 |
D |
$25.50 |
$742,662 |
D/D |
(29,124) |
0 |
0 |
- |
|
| RARX |
Ra Pharmaceuticals, Inc. |
Executive V.P. & CFO |
• – – |
2019-02-01 |
4 |
D |
$21.00 |
$69,111 |
D/D |
(3,291) |
7,126 |
0 |
- |
|
| RARX |
Ra Pharmaceuticals, Inc. |
Executive V.P. & CFO |
• – – |
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,417 |
10,417 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2015-08-14 |
4 |
AS |
$42.92 |
$407,740 |
D/D |
(9,500) |
69,270 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2015-08-14 |
4 |
OE |
$7.94 |
$75,430 |
D/D |
9,500 |
78,770 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2015-07-14 |
4 |
AS |
$48.92 |
$366,900 |
D/D |
(7,500) |
69,270 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2015-07-14 |
4 |
OE |
$2.03 |
$25,278 |
D/D |
7,500 |
76,770 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2015-06-15 |
4 |
AS |
$41.67 |
$312,525 |
D/D |
(7,500) |
69,270 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2015-06-15 |
4 |
OE |
$2.03 |
$15,225 |
D/D |
7,500 |
76,770 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2015-06-12 |
4 |
AS |
$41.29 |
$412,900 |
D/D |
(10,000) |
69,270 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2015-05-14 |
4 |
AS |
$39.28 |
$589,200 |
D/D |
(15,000) |
79,270 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2015-05-14 |
4 |
OE |
$2.03 |
$30,450 |
D/D |
15,000 |
86,586 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2014-06-17 |
4 |
AS |
$12.51 |
$169,260 |
D/D |
(13,530) |
78,463 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2014-03-06 |
4 |
AS |
$13.65 |
$61,562 |
D/D |
(4,510) |
91,993 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2014-02-12 |
4 |
AS |
$13.92 |
$62,724 |
D/D |
(4,506) |
96,503 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2014-02-07 |
4 |
AS |
$14.22 |
$141,176 |
D/D |
(9,928) |
101,009 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – – |
2014-02-07 |
4 |
OE |
$0.87 |
$139,435 |
D/D |
88,391 |
110,937 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFO |
• – • |
2013-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
10,297 |
22,546 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
SVP and CFOOfficer |
• – • |
2013-03-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,379 |
|
- |
|
22 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
